H1N1 vaccination in Sjogren's syndrome triggers polyclonal B cell activation and promotes autoantibody production

Annals of the Rheumatic Diseases

Volumn 76, Issue 10, 2017, Pages 1755-1763

  Brauner, Susanna ^a   Folkersen, Lasse ^a   Kvarnström, Marika ^a   Meisgen, Sabrina ^a   Petersen, Sven ^a   Franzén Malmros, Michaela ^a   Mofors, Johannes ^a   Brokstad, Karl A ^b   Klareskog, Lars ^a   Jonsson, Roland ^b   Westerberg, Lisa S ^c   Trollmo, Christina ^a   Malmström, Vivianne ^a   Ambrosi, Aurelie ^a   Kuchroo, Vijay K ^d   Nordmark, Gunnel ^e   Wahren Herlenius, Marie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CD19 ANTIGEN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; SYNDECAN 1; TOLL LIKE RECEPTOR; ANTIRHEUMATIC AGENT; AUTOANTIGEN; CYTOKINE; HLA DR ANTIGEN; IMMUNOGLOBULIN D; INTERLEUKIN 10; RIBONUCLEOPROTEIN; SS-A ANTIGEN; SS-B ANTIGEN; TLR7 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSCRIPTOME; VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSOME; FEMALE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INFLUENZA VACCINATION; PLASMA CELL; PLASMABLAST; PRIORITY JOURNAL; SJOEGREN SYNDROME; SYMPTOM; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; EPSTEIN BARR VIRUS; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; VACCINATION;

ANTIBODIES, VIRAL; ANTIGENS, CD19; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; FEMALE; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HLA-DR ANTIGENS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-ALPHA; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; RIBONUCLEOPROTEINS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TRANSCRIPTOME; VACCINATION;

EID: 85030611479     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210509     Document Type: Article

References (46)

1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus Erythematosus during a 5-Year period: a multicenter prospective study of 1, 000 patients. Medicine 1999;78:167-75.
2. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
3. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002;34:147-53.
4. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic diseasemodifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011;63:1486-96.
5. Saad CG, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 nonadjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011;70:1068-73.
6. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;25:2605-15.
7. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
8. Ambrosi A, Wahren-Herlenius M. Update on the immunobiology of Sjögren's syndrome. Curr Opin Rheumatol 2015;27:468-75.
9. Hansen A, Lipsky PE, Dörner T. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005;17:558-65.
10. Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013;382:819-31.
11. Kvarnström M, Ottosson V, Nordmark B, et al. Incident cases of primary Sjögren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol 2015;44:135-42.
12. Del Porto F, Laganà B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006;24:3217-23.
13. Perdan-Pirkmajer K, Thallinger GG, Snoj N, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 2012;21:175-83.
14. Urowitz MB, Anton A, Ibanez D, et al. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. Arthritis Care Res 2011;63:1517-20.
15. Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immunemediated disease-a prospectively controlled vaccination study. Rheumatology 2012;51:695-700.
16. Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23- Th17 pathway. J Exp Med 2009;206:1661-71.
17. Wahren-Herlenius M, Muller S, Isenberg D. Analysis of B-cell epitopes of the Ro/SS-A autoantigen. Immunol Today 1999;20:234-40.
18. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
19. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011;70:968-72.
20. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002;8:2160-71.
21. Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95.
22. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68.
23. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009;10:285-96.
24. Cerutti A, Zan H, Schaffer A, et al. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. J Immunol 1998;5:2145-57.
25. Corcoran AE, Riddell A, Krooshoop D, et al. Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor. Nature 1998;391:904-7.
26. Fujieda S, Saxon A, Zhang K. Direct evidence that gamma 1 and gamma 3 switching in human B cells is interleukin-10 dependent. Mol Immunol 1996;17-18:1335-43.
27. Kikuchi K, Lai AY, Hsu CL, et al. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med 2005;201:1197-203.
28. Arpin C, Déchanet J, Van Kooten C, et al. Generation of memory B cells and plasma cells in vitro. Science 1995;268:720-2.
29. Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005;201:35-9.
30. Glaum MC, Narula S, Song D, et al. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J Allergy Clin Immunol 2009;123:224-30.
31. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004;173:4479-91.
32. He B, Santamaria R, Xu W, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010;11:836-45.
33. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
34. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
35. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810-6.
36. Kiefer K, Oropallo MA, Cancro MP, et al. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012;90:498-504.
37. McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. Nat Rev Immunol 2015;15:87-103.
38. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794-804.
39. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;304:452-60.
40. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012;14:R155.
41. Willis R, Seif AM, McGwin G, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a Multiethnic US cohort. Lupus 2012;21:830-5.
42. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62.
43. Jeisy-Scott V, Kim JH, Davis WG, et al. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutininspecific antibodies in response to the 2009 pandemic split vaccine in mice. J Virol 2012;86:10988-98.
44. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006;103:2770-5.
45. Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. Ann Rheum Dis 2014;73:1052-9.
46. Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014;312:249-58.